Prevention of influenza virus shedding and protection from lethal H1N1 challenge using a consensus 2009 H1N1 HA and NA adenovirus vector vaccine

Frank R. Jones, Elizabeth S. Gabitzsch, Younong Xu, Joseph P. Balint, Viktoriya Borisevich, Jennifer Smith, Jeanon Smith, Bihung Peng, Aida Walker, Magda Salazar, Slobodan Paessler

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

Vaccines against emerging pathogens such as the 2009 H1N1 pandemic virus can benefit from current technologies such as rapid genomic sequencing to construct the most biologically relevant vaccine. A novel platform (Ad5 [E1-, E2b-]) has been utilized to induce immune responses to various antigenic targets. We employed this vector platform to express hemagglutinin (HA) and neuraminidase (NA) genes from 2009 H1N1 pandemic viruses. Inserts were consensuses sequences designed from viral isolate sequences and the vaccine was rapidly constructed and produced. Vaccination induced H1N1 immune responses in mice, which afforded protection from lethal virus challenge. In ferrets, vaccination protected from disease development and significantly reduced viral titers in nasal washes. H1N1 cell mediated immunity as well as antibody induction correlated with the prevention of disease symptoms and reduction of virus replication. The Ad5 [E1-, E2b-] should be evaluated for the rapid development of effective vaccines against infectious diseases.

Original languageEnglish (US)
Pages (from-to)7020-7026
Number of pages7
JournalVaccine
Volume29
Issue number40
DOIs
StatePublished - Sep 16 2011

Fingerprint

Adenovirus Vaccines
Virus Shedding
vector vaccines
viral shedding
sialidase
Hemagglutinins
Neuraminidase
Adenoviridae
hemagglutinins
Orthomyxoviridae
lethal genes
Vaccines
vaccines
H1N1 Subtype Influenza A Virus
Pandemics
pandemic
viruses
Vaccination
vaccination
immune response

Keywords

  • Ad5 [E1-, E2b-]
  • Adenovirus vector
  • Cell mediated immunity
  • H1N1 vaccine
  • Hemagglutinin
  • Horizontal transmission
  • Influenza
  • Neuraminidase
  • Pandemic
  • Viral shedding

ASJC Scopus subject areas

  • Immunology and Microbiology(all)
  • Infectious Diseases
  • Public Health, Environmental and Occupational Health
  • veterinary(all)
  • Molecular Medicine

Cite this

Prevention of influenza virus shedding and protection from lethal H1N1 challenge using a consensus 2009 H1N1 HA and NA adenovirus vector vaccine. / Jones, Frank R.; Gabitzsch, Elizabeth S.; Xu, Younong; Balint, Joseph P.; Borisevich, Viktoriya; Smith, Jennifer; Smith, Jeanon; Peng, Bihung; Walker, Aida; Salazar, Magda; Paessler, Slobodan.

In: Vaccine, Vol. 29, No. 40, 16.09.2011, p. 7020-7026.

Research output: Contribution to journalArticle

Jones, FR, Gabitzsch, ES, Xu, Y, Balint, JP, Borisevich, V, Smith, J, Smith, J, Peng, B, Walker, A, Salazar, M & Paessler, S 2011, 'Prevention of influenza virus shedding and protection from lethal H1N1 challenge using a consensus 2009 H1N1 HA and NA adenovirus vector vaccine', Vaccine, vol. 29, no. 40, pp. 7020-7026. https://doi.org/10.1016/j.vaccine.2011.07.073
Jones, Frank R. ; Gabitzsch, Elizabeth S. ; Xu, Younong ; Balint, Joseph P. ; Borisevich, Viktoriya ; Smith, Jennifer ; Smith, Jeanon ; Peng, Bihung ; Walker, Aida ; Salazar, Magda ; Paessler, Slobodan. / Prevention of influenza virus shedding and protection from lethal H1N1 challenge using a consensus 2009 H1N1 HA and NA adenovirus vector vaccine. In: Vaccine. 2011 ; Vol. 29, No. 40. pp. 7020-7026.
@article{ae6533fcc9f34101949589fe43b0e7cc,
title = "Prevention of influenza virus shedding and protection from lethal H1N1 challenge using a consensus 2009 H1N1 HA and NA adenovirus vector vaccine",
abstract = "Vaccines against emerging pathogens such as the 2009 H1N1 pandemic virus can benefit from current technologies such as rapid genomic sequencing to construct the most biologically relevant vaccine. A novel platform (Ad5 [E1-, E2b-]) has been utilized to induce immune responses to various antigenic targets. We employed this vector platform to express hemagglutinin (HA) and neuraminidase (NA) genes from 2009 H1N1 pandemic viruses. Inserts were consensuses sequences designed from viral isolate sequences and the vaccine was rapidly constructed and produced. Vaccination induced H1N1 immune responses in mice, which afforded protection from lethal virus challenge. In ferrets, vaccination protected from disease development and significantly reduced viral titers in nasal washes. H1N1 cell mediated immunity as well as antibody induction correlated with the prevention of disease symptoms and reduction of virus replication. The Ad5 [E1-, E2b-] should be evaluated for the rapid development of effective vaccines against infectious diseases.",
keywords = "Ad5 [E1-, E2b-], Adenovirus vector, Cell mediated immunity, H1N1 vaccine, Hemagglutinin, Horizontal transmission, Influenza, Neuraminidase, Pandemic, Viral shedding",
author = "Jones, {Frank R.} and Gabitzsch, {Elizabeth S.} and Younong Xu and Balint, {Joseph P.} and Viktoriya Borisevich and Jennifer Smith and Jeanon Smith and Bihung Peng and Aida Walker and Magda Salazar and Slobodan Paessler",
year = "2011",
month = "9",
day = "16",
doi = "10.1016/j.vaccine.2011.07.073",
language = "English (US)",
volume = "29",
pages = "7020--7026",
journal = "Vaccine",
issn = "0264-410X",
publisher = "Elsevier BV",
number = "40",

}

TY - JOUR

T1 - Prevention of influenza virus shedding and protection from lethal H1N1 challenge using a consensus 2009 H1N1 HA and NA adenovirus vector vaccine

AU - Jones, Frank R.

AU - Gabitzsch, Elizabeth S.

AU - Xu, Younong

AU - Balint, Joseph P.

AU - Borisevich, Viktoriya

AU - Smith, Jennifer

AU - Smith, Jeanon

AU - Peng, Bihung

AU - Walker, Aida

AU - Salazar, Magda

AU - Paessler, Slobodan

PY - 2011/9/16

Y1 - 2011/9/16

N2 - Vaccines against emerging pathogens such as the 2009 H1N1 pandemic virus can benefit from current technologies such as rapid genomic sequencing to construct the most biologically relevant vaccine. A novel platform (Ad5 [E1-, E2b-]) has been utilized to induce immune responses to various antigenic targets. We employed this vector platform to express hemagglutinin (HA) and neuraminidase (NA) genes from 2009 H1N1 pandemic viruses. Inserts were consensuses sequences designed from viral isolate sequences and the vaccine was rapidly constructed and produced. Vaccination induced H1N1 immune responses in mice, which afforded protection from lethal virus challenge. In ferrets, vaccination protected from disease development and significantly reduced viral titers in nasal washes. H1N1 cell mediated immunity as well as antibody induction correlated with the prevention of disease symptoms and reduction of virus replication. The Ad5 [E1-, E2b-] should be evaluated for the rapid development of effective vaccines against infectious diseases.

AB - Vaccines against emerging pathogens such as the 2009 H1N1 pandemic virus can benefit from current technologies such as rapid genomic sequencing to construct the most biologically relevant vaccine. A novel platform (Ad5 [E1-, E2b-]) has been utilized to induce immune responses to various antigenic targets. We employed this vector platform to express hemagglutinin (HA) and neuraminidase (NA) genes from 2009 H1N1 pandemic viruses. Inserts were consensuses sequences designed from viral isolate sequences and the vaccine was rapidly constructed and produced. Vaccination induced H1N1 immune responses in mice, which afforded protection from lethal virus challenge. In ferrets, vaccination protected from disease development and significantly reduced viral titers in nasal washes. H1N1 cell mediated immunity as well as antibody induction correlated with the prevention of disease symptoms and reduction of virus replication. The Ad5 [E1-, E2b-] should be evaluated for the rapid development of effective vaccines against infectious diseases.

KW - Ad5 [E1-, E2b-]

KW - Adenovirus vector

KW - Cell mediated immunity

KW - H1N1 vaccine

KW - Hemagglutinin

KW - Horizontal transmission

KW - Influenza

KW - Neuraminidase

KW - Pandemic

KW - Viral shedding

UR - http://www.scopus.com/inward/record.url?scp=80052327605&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80052327605&partnerID=8YFLogxK

U2 - 10.1016/j.vaccine.2011.07.073

DO - 10.1016/j.vaccine.2011.07.073

M3 - Article

VL - 29

SP - 7020

EP - 7026

JO - Vaccine

JF - Vaccine

SN - 0264-410X

IS - 40

ER -